Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2017; 16: 69-74
Острый миелоидный лейкоз у детей с транслокацией t(8;16)(p11;p13)
https://doi.org/10.24287/1726-1708-2017-16-4-69-74Аннотация
Список литературы
1. Баровская Ю.А. Современные аспекты диагностики и лечения острого миелоидного лейкоза у детей (обзор литературы). Вопросы гематологии/онкологии и иммунологии в педиатрии, 2015; 14 (3): 48-54.
2. Рукавицин О.А. Гематология: национальное руководство. - М.: ГЭОТАР-Медиа, 2015, с. 183.
3. Rubnitz J.E. How I treat pediatric acute myeloid leukemia. Blood 2012; 119 (25): 5980-8.
4. Coenen E.A., Zwaan C.M., Reinhardt D., Harrison C.J., Haas O.A., de Haas V., Mihál V., et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 2013; 122 (15); 2704-14.
5. Mo J., Lampkin B., Perentesis J., Poole L., Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genetics and Cytogenetics 2006; 165: 75-8.
6. Haferlach T., Kohlmann A., Klein H.U., Ruckert C., Dugas M., Williams P.M., Kern W., et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic leatures. Leukemia 2009; 23: 934-43.
7. Баровская Ю.А., Алейникова О.В. Результаты лечения острого миело-идного лейкоза у детей по протоколу ОМЛ-ММ-2006 в Республике Бела-русь. Медицинский журнал, 2014, 4 (50): 56-9.
8. Maschan M., Shelikhova L., Ilushina M., Kurnikova E., Boyakova E., Balashov D., et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant 2016 May; 51 (5): 668-74.
9. Williams D.C. Jr., Massey G.V., Russell E.C., Riley R.S., Ben-Ezra J. Translocation-positive acute myeloid leukemia associated with valproic acid therapy. Pediatr Blood Cancer 2008; 50 (3): 641-3.
10. Camós M., Esteve J., Jares P., Colomer D., Rozman M., Villamor N., Costa D., Carrió A., Nomdedéu J., Montserrat E., Campo E. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 2006; 66: 6947-54.
11. Díaz-Beyá M., Navarro A., Ferrer G., Díaz T., Gel B., Camós M., Pratcorona M., Torrebadell M., Rozman M., Colomer D., Monzo M. and Esteve J. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia 2013 Mar; 27 (3): 595-603.
12. Hanada T., Kanamitsu K., Chayama K., Miyamura T., Kanazawa Y., Muraoka M., Washio K., et al. A Long-term Survivor after Congenital Acute Myeloid Leukemia with t(8; 16)(p11; p13). Acta Med Okayama 2006; 70 (1): 31-5.
13. Daifu T., Kato I., Kozuki K., Umeda K., Hiramatsu H., Watanabe K., Kamiya I., et al. The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia. Journal of Pediatric Hematology Oncology 2014; 36: 325-7.
Pediatric Hematology/Oncology and Immunopathology. 2017; 16: 69-74
Childhood acute myeloid leukemia with the t(8;16)(p11;p13) translocation
https://doi.org/10.24287/1726-1708-2017-16-4-69-74Abstract
Acute myeloid leukemia is a clonal systemic disease of the hematologic system, which includes heterogeneous group of diseases. Therefore optimization of methods of treatment of this pathology is an important task. More than 1% of AML with rare translocations can not be strictly divided into risk groups. There are also discrepancies between different researchers’ data on the same cytogenetic abnormalities. In this article we present the experience of diagnostics and therapy of the patient with the rare sub-type of AML with the t(8;16)(p11;p13) translocation in Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology. The patient received high-dose chemotherapy and allogeneic hematopoietic stem cell transplant. According to catamnesis the child (1.5 years) has been in the clinico-hematological and cytogenetic remission.
References
1. Barovskaya Yu.A. Sovremennye aspekty diagnostiki i lecheniya ostrogo mieloidnogo leikoza u detei (obzor literatury). Voprosy gematologii/onkologii i immunologii v pediatrii, 2015; 14 (3): 48-54.
2. Rukavitsin O.A. Gematologiya: natsional'noe rukovodstvo. - M.: GEOTAR-Media, 2015, s. 183.
3. Rubnitz J.E. How I treat pediatric acute myeloid leukemia. Blood 2012; 119 (25): 5980-8.
4. Coenen E.A., Zwaan C.M., Reinhardt D., Harrison C.J., Haas O.A., de Haas V., Mihál V., et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood 2013; 122 (15); 2704-14.
5. Mo J., Lampkin B., Perentesis J., Poole L., Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genetics and Cytogenetics 2006; 165: 75-8.
6. Haferlach T., Kohlmann A., Klein H.U., Ruckert C., Dugas M., Williams P.M., Kern W., et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic leatures. Leukemia 2009; 23: 934-43.
7. Barovskaya Yu.A., Aleinikova O.V. Rezul'taty lecheniya ostrogo mielo-idnogo leikoza u detei po protokolu OML-MM-2006 v Respublike Bela-rus'. Meditsinskii zhurnal, 2014, 4 (50): 56-9.
8. Maschan M., Shelikhova L., Ilushina M., Kurnikova E., Boyakova E., Balashov D., et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant 2016 May; 51 (5): 668-74.
9. Williams D.C. Jr., Massey G.V., Russell E.C., Riley R.S., Ben-Ezra J. Translocation-positive acute myeloid leukemia associated with valproic acid therapy. Pediatr Blood Cancer 2008; 50 (3): 641-3.
10. Camós M., Esteve J., Jares P., Colomer D., Rozman M., Villamor N., Costa D., Carrió A., Nomdedéu J., Montserrat E., Campo E. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 2006; 66: 6947-54.
11. Díaz-Beyá M., Navarro A., Ferrer G., Díaz T., Gel B., Camós M., Pratcorona M., Torrebadell M., Rozman M., Colomer D., Monzo M. and Esteve J. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. Leukemia 2013 Mar; 27 (3): 595-603.
12. Hanada T., Kanamitsu K., Chayama K., Miyamura T., Kanazawa Y., Muraoka M., Washio K., et al. A Long-term Survivor after Congenital Acute Myeloid Leukemia with t(8; 16)(p11; p13). Acta Med Okayama 2006; 70 (1): 31-5.
13. Daifu T., Kato I., Kozuki K., Umeda K., Hiramatsu H., Watanabe K., Kamiya I., et al. The clinical utility of genetic testing for t(8;16)(p11;p13) in congenital acute myeloid leukemia. Journal of Pediatric Hematology Oncology 2014; 36: 325-7.
